EugeneSomozaMD

Neurology • Cincinnati, OH

Addiction Medicine

Physician

Join to view full profile

Dr. Somoza is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Somoza's full profile

Already have an account?

Office
3200 Vine St
Cincinnati, OH 45220
Phone+1 513-487-7800

Education & Training

University of Cincinnati Medical Center/College of MedicineResidency, Psychiatry, 1982 - 1984
University of Cincinnati Medical Center Inc.Internship, Transitional Year, 1980 - 1981
Autonomous University of Madrid Class of 1980

Certifications & Licensure

OH State Medical License 1984 - 2020
IN State Medical License 2007 - 2015
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1 Start of enrollment: 1996 Nov 01
Completed
Phase 2
Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2 Start of enrollment: 1996 Nov 01
Completed
Phase 1
Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 Start of enrollment: 1998 Sep 01
Completed
Phase 2
Cocaine-Methylphendidate Interaction Study - 4 Start of enrollment: 1997 Dec 01
Completed
Phase 1
Naltrexone in Treatment of Cocaine Dependence - 5 Start of enrollment: 1995 May 01
Completed
Phase 2
Resperine, Gabapentin, or Lamotrigine for the Treatment of Cocaine Dependence: 2 - 7 Start of enrollment: 1997 Nov 01
Completed
Phase 2
Tiagabine, Sertraline, or Donepezil for the Treatment of Cocaine Dependence - 9 Start of enrollment: 1999 Mar 01
Completed
Phase 2
Reserpine for the Treatment of Cocaine Dependence - 1 Start of enrollment: 2001 Jul 01
Completed
Phase 2
Tiagabine for the Treatment of Cocaine Dependence - 1 Start of enrollment: 2002 Oct 01
Completed
Phase 2
Safety Assessment of Potential Interactions Between IV Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH) Start of enrollment: 2008 Jan 01
Completed
Phase 1
Vigabatrin for Treatment of Cocaine Dependence Start of enrollment: 2008 Jan 01
Completed
Phase 2
Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy Start of enrollment: 2016 Aug 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

11 citations
Major Depressive Disorder and Dysthymia at the Intersection of Nativity and Racial–Ethnic Origins
Magdalena Szaflarski, Lisa A. Cubbins, Shawn Bauldry, Karthikeyan Meganathan, Daniel H. Klepinger
Journal of Immigrant and Minority Health. 2016-08-01
39 citations
Total antioxidant capacity is significantly lower in cocaine-dependent and methamphetamine-dependent patients relative to normal controls: results from a preliminary s...
Jessica Walker, Theresa Winhusen, Jayne M. Storkson, Daniel Lewis, Michael W. Pariza
Human Psychopharmacology. 2014-11-01
95 citations
Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial
Thomas R. Kosten, Coreen B. Domingo, Daryl Shorter, Frank M. Orson, Charles Green
Drug and Alcohol Dependence. 2014-07-01

Press Mentions

Icd 9 Major DepressionOctober 7th, 2017
Colorado School of Public HealthMay 11th, 2020

Professional Memberships

American Society of Addiction Medicine - ASAM
Member